| アブストラクト | BACKGROUND: Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) that has been approved by the FDA for patients with locally advanced or metastatic urothelial carcinoma (UC). This study presents a comprehensive pharmacovigilance analysis of the post-marketing safety profile of EV in the real-world based on the US Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: Adverse event (AE) reports regarding EV between January 2020 and December 2023 were obtained from the FAERS database. The standardized MedDRA query (SMQ) narrow search AEs on the preferred term (PT) level were used. Disproportionality analysis was performed to identify the AE signals for EV with the reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN). RESULTS: A total of 2,216 reports regarding EV were included in the present study. SMQ analysis results indicated that a stronger strength signal was found in severe cutaneous adverse reactions, retroperitoneal fibrosis, and peripheral neuropathy. A total of 116 significant disproportionality PTs referring to 14 system organ classes (SOCs) were retained by disproportionality analysis, with 49 PTs not listed on the EV drug label. Frequently reported EV-related AEs included rash, peripheral neuropathy, decreased appetite, alopecia, and pruritus. The time to onset of the majority of EV-related AEs was within 30 days (66.05%), with only 0.73% events occurring after 1 year. CONCLUSION: The disproportionality analysis highlights that dermatologic toxicity and peripheral neuropathy were the major AEs induced by EV. The potential AEs not listed on the drug label were mainly related to gastrointestinal, hepatic, and pulmonary events. Further research is needed to confirm and explore the EV-related AEs in clinical practice. |
|---|
| ジャーナル名 | Frontiers in immunology |
|---|
| Pubmed追加日 | 2024/9/5 |
|---|
| 投稿者 | Yu, Mingming; Zhou, Lijun; Cao, Mengda; Ji, Chunmei; Zheng, Yuanyi |
|---|
| 組織名 | Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated;Sixth People's Hospital, Shanghai, China.;Department of Urology, Shanghai Children's Hospital, Shanghai Jiao Tong;University, Shanghai, China.;Department of Pharmacy, Zhongda Hospital, School of Medicine, Southeast;University, Nanjing, China.;Department of Pharmacy, First Affiliated Hospital of Nanjing Medical University,;Nanjing, Jiangsu, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39234238/ |
|---|
